Spots Global Cancer Trial Database for Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
Official Title: A Multicenter, Open-Label, Phase I/II Study of EOS884448 (EOS-448) in Combination With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
Study ID: NCT05060432
Study Description
Brief Summary: This is a multicenter, open-label, phase I/II basket study, evaluating the safety, tolerability, RP2D, pharmacokinetics, pharmacodynamics and antitumor activity of EOS-448 (also known as GSK4428859A or belrestotug) combined with standard of care and/or with investigational therapies in participants with advanced solid tumors.
Detailed Description: The combinations evaluated will be: * EOS-448 combined with pembrolizumab, an anti-PD-1 antibody * EOS-448 combined with inupadenant an investigational adenosine A2A receptor antagonist * EOS-448 combined with dostarlimab an anti-PD-1 antibody * inupadenant combined with dostarlimab * EOS-448 combined with inupadenant and dostarlimab * EOS-448 combined with dostarlimab and standard of care chemotherapies in participants with NSCLC
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of California San Diego, San Diego, California, United States
Innovative Clinical Research Institute, LLC, Whittier, California, United States
Clermont Oncology Center, Clermont, Florida, United States
Alpha Oncology Research, Orange City, Florida, United States
University of Kentucky, Markey Cancer Center, Lexington, Kentucky, United States
Norton Cancer Institute, Louisville, Kentucky, United States
Hackensack University Medical Center, Bergen, New Jersey, United States
The Gabrail Pharmacology Phase 1 Research Center LLC, Canton, Ohio, United States
University of Pittsburg Medical Center, Pittsburgh, Pennsylvania, United States
GZA Ziekenhuizen campus Sint-Augustinus, Antwerpen, Antwerp, Belgium
Cliniques universitaires St Luc-UCL, Brussels, , Belgium
Jessa Ziekenhuis, Hasselt, , Belgium
UZ Leuven, Leuven, , Belgium
Hôpital Saint André, Bordeaux, , France
CHU Caen, Caen, , France
Centre Georges Francois Leclerc, Dijon, , France
Clinique Victor Hugo, Le Mans, , France
Centre Léon Bérard, Lyon, , France
Institut de Cancérologie de l'Ouest, Nantes, , France
Centre Antoine Lacassagne, Nice, , France
Pitié Salpêtrière, Paris, , France
CHU de POITIERS, Poitiers, , France
ICANS, Strasbourg, , France
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRCCS (Meldola), Meldola, , Italy
Istituto Europeo di Oncologia, Milano, , Italy
Universita degli Studi di Pavia - Fondazione IRCCS Policlinico San Matteo, Pavia, , Italy
Hospital Universitario de Badajoz, Badajoz, , Spain
UOMI Cancer Center-Clinica Tres Torres, Barcelona, , Spain
Hospital de la Santa Creu i Sant Pau, Barcelona, , Spain
Vall d'Hebron, Barcelona, , Spain
Consorcio Hospitalario Provincial de Castello, Castelló, , Spain
Hospital Universitario de Jaen, Jaén, , Spain
Hospital Clinico San Carlos, Madrid, , Spain
Hospital Universitario Fundación Jiménez Díaz, Madrid, , Spain
Hospital Universitario 12 de Octubre, Madrid, , Spain
Hospital Universitario Puerta de Hierro de Majadahonda, Majadahonda, , Spain
Hospital Universitario de Navarra (Pamplona), Pamplona, , Spain
Hospital Universitario de Navarra, Pamplona, , Spain
Hospital Universitario Virgen Macarena, Sevilla, , Spain
Hospital Universitari i Politecnic La Fe de Valencia (Hospital La Fe Bulevar Sur), Valencia, , Spain
Hammersmith Hospital, London, , United Kingdom
Contact Details
Name: Iteos Clinical Trials
Affiliation: iTeos Belgium SA
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
